The following serious adverse reactions are described in greater detail elsewhere in labeling: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice
Pharmacists also need to counsel patients who may have started the diet by themselves about its benefits and the risks
What contraindications does the post list for tirzepatide regardless of formulation
A clinician can explain whether an approved option or a study-related option is relevant to your care
For most patients starting GLP-1 treatment for weight management, semaglutide (either Wegovy or compounded) is a common first choice because it has the longest track record, the most clinical data, and the widest availability
Tanaka S, Yoshimore Y, Kawaski R